Status: Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Participants needed: 200
Trial details
Phase: Phase 3Age: 16-70Biological sex: AllType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: May 29, 2026Locations: 46
Eligibility criteria
Clinical and genetic diagnosis of FSHD1 or FSHD2 [+2]
Breastfeeding, pregnancy, or intent to become pregnant during the study [+5]